🇺🇸 MET233 and MET097 in United States

MET233 and MET097 (met233-and-met097) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

MET233 and MET097 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is MET233 and MET097 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for MET233 and MET097 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does MET233 and MET097 cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.